iFCG: a promising new regimen for treating IGHV-mutated CLL
How to overcome resistance to new compounds in CLL
What should we be focusing on in CLL research?
BGB-3111 and ibrutinib for Waldenström’s macroglobulinemia
Overview of 3 studies on CLL therapy: data on ibrutinib and a ROR1 inhibitor